Evidence map›Paper›PMID 27144110›Full record

ArticleRespiratory medicine case reports2016

A case of vildagliptin-induced interstitial pneumonia.

Naoyuki Kuse, Shinji Abe, Hidehiko Kuribayashi, Minoru Inomata, Hitoshi Saito, Yuh Fukuda, Akihiko Gemma

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Interstitial lung disease and diabetes.World journal of diabetes · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Naoyuki KuseDivision of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10 Ebisu Shibuya-ku, Tokyo, 150-0013, Japan; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo, 113-8602, Japan.
Shinji AbeDivision of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10 Ebisu Shibuya-ku, Tokyo, 150-0013, Japan.
Hidehiko KuribayashiDivision of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10 Ebisu Shibuya-ku, Tokyo, 150-0013, Japan.
Minoru InomataDivision of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10 Ebisu Shibuya-ku, Tokyo, 150-0013, Japan.
Hitoshi SaitoDivision of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10 Ebisu Shibuya-ku, Tokyo, 150-0013, Japan.
Yuh FukudaDivision of Diagnostic Pathology, Itabashi Chuo Medical Center, 2-12-7 Azusawa Itabashi-ku, Tokyo, 174-0051, Japan.
Akihiko GemmaDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo, 113-8602, Japan.
Tokyo Metropolitan Hiroo Hospital · JPMie Chuo Medical Center · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 65-year-old Japanese male with type 2 diabetes mellitus was admitted to our hospital with a productive cough and worsening dyspnea. He had started receiving vildagliptin, which is one of the dipeptideylpeptidase-4 (DPP-4) inhibitors, several days before the appearance of his symptoms. Laboratory findings revealed markedly elevated levels of immunoglobulin E and Krebs von den Lungen-6. Chest computed tomography revealed ground-glass opacity with irregular reticulation throughout both lungs. Biopsy specimens by transbronchial lung biopsy showed subacute interstitial pneumonia and an organizing pneumonia pattern with acute alveolar injury. The drug lymphocyte stimulation test showed a positive result for vildagliptin. Withdrawal of vildagliptin and administration of glucocorticoid treatment improved his respiratory condition and radiological findings. Therefore, we diagnosed the patient with vildagliptin-induced interstitial pneumonia based on both his clinical course and pathological findings. Interstitial pneumonia as a side effect of vildagliptin is rare. It may be necessary to monitor the respiratory condition of patients upon administration of DPP-4 inhibitors until further evidence is obtained.

Indexed as

BAL, bronchoalveolar lavageCT, computed tomographyDLST, drug lymphocyte stimulation testsDPP-4, dipeptideylpeptidase-4DPP-4 inhibitorDrug-induced lung injuryFVC, forced vital capacityIgE, immunoglobulin EIPAF, interstitial pneumonia with autoimmune featuresKL-6, Krebs von den Lungen-6PFT, pulmonary function testingT2DM, type 2 diabetes mellitusTBLB, transbronchial lung biopsyVildagliptin

Identifiers

PMID27144110
PMCPMC4840426
OpenAlexW2293062471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.